Summary
Johnson & Johnson's (JNJ) 2016 10-K filing shows a company with strong and diversified healthcare operations across three segments: Consumer, Pharmaceutical, and Medical Devices. The company reported total sales of $71.9 billion, a 2.6% increase year-over-year, driven by operational growth across its segments, particularly in Pharmaceuticals. The Pharmaceutical segment saw robust growth in its immunology portfolio with key drugs like STELARA® and SIMPONI® showing significant increases, while Oncology also performed well with strong uptake of IMBRUVICA® and DARZALEX®. The Medical Devices segment remained relatively flat in sales, impacted by divestitures and competitive pressures, though Vision Care showed positive growth. The Consumer segment experienced a slight sales decline, impacted by the Venezuela operations and divestitures, but saw strong performance in its Beauty and OTC product lines. The company continues to invest heavily in research and development ($9.1 billion in 2016) to fuel future innovation and offset patent expirations. However, a key risk highlighted is the impending biosimilar competition for its major product, REMICADE®, which is expected to impact U.S. sales significantly. Financially, JNJ demonstrated solid performance with net earnings of $16.5 billion. The company maintained a strong cash flow from operations ($18.8 billion) and actively returned capital to shareholders through dividends ($8.6 billion) and share repurchases ($9.0 billion). Despite some segment-specific challenges and ongoing legal proceedings, the company's diversified business model and commitment to innovation appear to position it for continued resilience. Investors should monitor the impact of REMICADE® biosimilar competition and the company's ability to successfully launch new products to mitigate this risk.
Financial Highlights
53 data points| Revenue | $76.45B |
| Cost of Revenue | $25.44B |
| Gross Profit | $51.01B |
| SG&A Expenses | $21.52B |
| Interest Expense | $934.00M |
| Net Income | $1.30B |
| EPS (Basic) | $0.48 |
| EPS (Diluted) | $0.47 |
| Shares Outstanding (Basic) | 2.69B |
| Shares Outstanding (Diluted) | 2.75B |
Key Highlights
- 1Total sales increased by 2.6% to $71.9 billion in 2016, driven by operational growth, partially offset by currency impacts.
- 2The Pharmaceutical segment reported sales of $33.5 billion, up 6.5%, with strong performance in Immunology (REMICADE®, STELARA®, SIMPONI®) and Oncology (IMBRUVICA®, DARZALEX®).
- 3The Consumer segment reported sales of $13.3 billion, a decrease of 1.5%, impacted by currency, divestitures, and operations in Venezuela, though Beauty and OTC franchises showed growth.
- 4The Medical Devices segment reported sales of $25.1 billion, a slight decrease of 0.1%, affected by divestitures and pricing pressures, but Vision Care saw 6.8% growth.
- 5Research and Development (R&D) expenses were $9.1 billion in 2016, representing 12.7% of sales, underscoring a commitment to innovation.
- 6The company repurchased $9.0 billion of its common stock during 2016 and increased its dividend for the 54th consecutive year.
- 7Significant risk identified is the introduction of biosimilar competition for REMICADE® in the U.S. market, expected to reduce sales.